- Home
- ALVO vs INVA Comparison
ALVO vs INVA Comparison
Compare ALVO & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.95
HOLD
Current Price
$20.04
Company Overview
Basic Information| Metric | ALVO | INVA |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | ALVO | INVA |
|---|---|---|
| Price | $4.95 | $20.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $9.25 | ★ $36.80 |
| AVG Volume (30 Days) | 593.5K | ★ 845.1K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.96 |
| EPS | 0.24 | ★ 1.52 |
| Revenue | ★ $573,350,000.00 | $388,521,000.00 |
| Revenue This Year | $20.97 | $13.23 |
| Revenue Next Year | $43.04 | $8.62 |
| P/E Ratio | $19.70 | ★ $13.16 |
| Revenue Growth | ★ 45.55 | 10.14 |
| 52 Week Low | $4.32 | $16.52 |
| 52 Week High | $13.70 | $22.76 |
Technical Indicators
Market Signals| Indicator | ALVO | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 45.18 |
| Support Level | $4.67 | $19.72 |
| Resistance Level | $5.85 | $21.00 |
| Average True Range (ATR) | 0.36 | 0.52 |
| MACD | 0.03 | -0.18 |
| Stochastic Oscillator | 36.93 | 30.82 |
Price Performance
Historical Comparison ALVO
INVA
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.